Brian Miller, MD, PhD, MPH.

RESEARCH UPDATE

Aripiprazole-Related Psychotic Exacerbations

January 1, 2023

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

This study identifies a common clinical scenario where aripiprazole may trigger psychotic symptoms.

RESEARCH UPDATE

Topiramate Improves Weight in Schizophrenia in South Asians

June 1, 2022

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This study looked at adjunctive topiramate for weight in a patient population inherently more vulnerable to cardiometabolic disturbance.

RESEARCH UPDATE

Anticholinergic-Associated Cognitive Impairment in Schizophrenia

April 5, 2022

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Antipsychotics, benztropine, and antidepressants have anticholinergic properties that can impair cognition. A study takes a deep dive into the magnitude of the risk of dementia in schizophrenia.

Vitamin B6 Lowers Prolactin on Antipsychotics

March 4, 2022

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Higher antipsychotic doses are more likely to elevate prolactin. Enter: Vitamin B6.